Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $124 | $20 | $27 | $33 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $3 | $1 | $1 |
| Total Curr. Assets | $127 | $23 | $29 | $34 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $1 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $128 | $24 | $29 | $35 |
| Liabilities | – | – | – | – |
| Payables | $5 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $3 | $2 | $3 |
| Total Curr. Liab. | $5 | $3 | $2 | $3 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $5 | $3 | $2 | $3 |
| Equity | – | – | – | – |
| Pref Stock | $44 | $32 | $32 | $32 |
| Common Stock | $266 | $117 | $117 | $116 |
| Retained Earnings | -$213 | -$147 | -$138 | -$131 |
| AOCI | -$5 | -$3 | -$4 | -$4 |
| Other Equity | $33 | $23 | $22 | $21 |
| Total Equity | $125 | $23 | $29 | $33 |
| Supplemental Information | – | – | – | – |
| Minority Interest | -$2 | -$2 | -$2 | -$2 |
| Total Liab. & Tot. Equity | $128 | $24 | $29 | $35 |
| Net Debt | -$124 | -$20 | -$27 | -$33 |